Buy Rating Affirmed for Scholar Rock Holding on Strong Drug …

May 23, 2024 · H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) today and set a price target of $30.00.. Andres Y. …

$30.00
OFF

Buy Rating Affirmed For Scholar Rock Holding On Strong Drug …

2 weeks from now

May 23, 2024 · H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) today and set a price target of $30.00.. Andres Y. …

businessinsider.com

$35.00
OFF

Buy Rating On Scholar Rock Holding: Promising Phase 3 Results …

2 weeks from now

Oct 7, 2024 · H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Scholar Rock Holding (SRRK – Research Report) today and set a price target of $35.00.. Andres Y. …

businessinsider.com

$36.00
OFF

Scholar Rock Shares Target Increased, Holds Buy On SMA Drug …

2 weeks from now

Nov 25, 2024 · Monday, Truist Securities adjusted its outlook on Scholar Rock (NASDAQ:SRRK) shares, raising the biotechnology company's price target from $36.00 to $45.00 while …

investing.com

42%
OFF

Scholar Rock Stock Target Increased, Buy Rating On SMA Study Results

2 weeks from now

Scholar Rock has demonstrated impressive stock performance, with a 300.42% price return over the last three months and a 221.29% return over the past year, aligning with H.C. Wainwright's …

investing.com

$30.00
OFF

Buy Rating Justified By Scholar Rock’s Promising Drug Trials And …

2 weeks from now

Aug 9, 2024 · Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Scholar Rock Holding (SRRK – Research Report) and keeping the price target at $30.00.. …

businessinsider.com

$29.67
OFF

Scholar Rock Holding (SRRK) Stock Rockets Up On Positive Phase …

2 weeks from now

Oct 9, 2024 · Scholar Rock Holding is rated a Strong Buy based on the cumulative recommendations of five analysts. The average price target for SRRK stock is $29.67 , …

nasdaq.com

30%
OFF

Scholar Rock Scores With ‘surprise’ Success In SMA Drug Study

2 weeks from now

Oct 7, 2024 · Additionally, 30% of those on Scholar Rock’s drug had at least a three-point improvement on a ratings scale widely used to evaluate SMA therapies. By comparison, …

yahoo.com

362%
OFF

SRRK Stock Soars As Muscle Disease Drug Meets Phase III Study Goal

2 weeks from now

Oct 8, 2024 · Shares of Scholar Rock SRRK skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and …

nasdaq.com

11%
OFF

Here's Why Everybody's Talking About Scholar Rock Right Now

2 weeks from now

Oct 9, 2024 · Shares of Scholar Rock (SRRK-5.11%) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's …

fool.com

440%
OFF

Here’s Why Scholar Rock Holding Corporation (SRRK) Is …

2 weeks from now

2 days ago · Scholar Rock Holding Corporation (NASDAQ:SRRK) Q4 Returns as of December 31, 2024: 440% In Q4 2024, SRRK’s stock price returned nearly 440%, going from $8.01 on …

yahoo.com

$29.00
OFF

Buy Rating Affirmed For Scholar Rock On Promising SRK-181 Trial …

2 weeks from now

Jun 5, 2024 · Analyst Etzer Darout of BMO Capital assigned a Buy rating on Scholar Rock Holding (SRRK – Research Report), retaining the price target of $29.00.. Etzer Darout has …

businessinsider.com

FAQs about Buy Rating Affirmed for Scholar Rock Holding on Strong Drug … Coupon?

What is the price target for scholar rock holding (srk-439)?

The associated price target remains the same with $30.00. Andres Y. Maldonado has given his Buy rating due to a combination of factors concerning Scholar Rock Holding’s promising preclinical profile for their myostatin inhibitor, SRK-439. ...

Should you buy scholar rock holding (SRRK – research report)?

Truist Financial analyst Jailendra Singh reiterated a Buy rating on Scholar Rock Holding (SRRK – Research Report) today. The company’s shares closed last Friday at $40.49. According to TipRanks, Singh is an analyst with an average return of -15.0% and a 32.26% success rate. ...

Is scholar rock holding a good buy?

According to TipRanks, Singh is an analyst with an average return of -15.0% and a 32.26% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Icon, and IQVIA Holdings. Currently, the analyst consensus on Scholar Rock Holding is a Strong Buy with an average price target of $42.40. ...

Is scholar rock a good SMA drug?

Additionally, 30% of those on Scholar Rock’s drug had at least a three-point improvement on a ratings scale widely used to evaluate SMA therapies. By comparison, 12.5% of placebo recipients hit that mark. ...

Is scholar rock a good stock to buy for the Embraze trial?

At recent prices, Scholar Rock boasts a $2.5 billion market cap. This is an appropriate valuation for a company likely to earn approval for an SMA treatment late next year. That said, this stock's present valuation isn't pricing in any success for the Embraze trial. Scholar Rock is a high-risk stock best avoided by most individual investors. ...

Is scholar rock a good Biotech stock to buy?

Investors may find this surging biotech stock an intriguing option with growth potential. Scholar Rock is a clinical-stage biopharmaceutical company specializing in severe diseases with insufficient current treatments. ...